The tweet was deleted by the author.
But we saved everything 🙂.
Vir Biotechnology disclosed its second quarter 2026 financial results, revealing a robust cash position exceeding 1.0 billion dollars.
The company reported ongoing progress in its chronic hepatitis delta (CHD) and oncology portfolios, supporting its development pipeline. The disclosed financial strength and clinical focus underscore Vir Biotechnology's efforts to cement its standing in biopharma innovation.
View post on X Loading...
Vir Biotechnology had previously announced plans to release its second quarter 2026 financial results and hold an investor call on August 5 in an earlier notice to investors. The scheduled update drew investor attention ahead of today's disclosure. The prior communication focused on the timing of the release and engagement with shareholders.